According to GlobalData, Phase II drugs for Lung Injury does not have sufficient historical ... trials by using mesenchymal stem cells to treat patients suffering with advanced stages of AIDS. The ...

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Non-Small Cell Lung Cancer.

Roche RHHBY announced that the late-stage study evaluating the combination therapy of tiragolumab plus Tecentriq ...

Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting ...

locally advanced unresectable or metastatic non-squamous non-small cell lung cancer (nSq NSCLC), did not meet its primary endpoints of progression-free survival (PFS) at its primary analysis with a ...

A new technology now being offered at Community Regional is helping doctors detect lung cancer far sooner than ever before.

Investigators compared cost-effectiveness of the KRAS inhibitor sotorasib against the taxane docetaxel in the second line for ...

Johnson & Johnson (JNJ) announced that Health Canada has issued a Notice of Compliance for RYBREVANT in combination with ...

One of the other presentations I'll just highlight is that one of our residents at Yale actually had a presentation yesterday ...

For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), amivantamab-lazertinib yields improved progression-free survival compared with osimertinib as first-line treatment.

If you or a loved one are considering volunteering for an ovarian cancer clinical trial, here’s what to know about the ...

On June 12, 2024, the FDA granted traditional approval to selpercatinib for the treatment of for adult and pediatric patients ...